Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation (Q39084910)
Jump to navigation
Jump to search
scientific article published on 8 November 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation |
scientific article published on 8 November 2013 |
Statements
1 reference
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation (English)
1 reference
Kazuma Ohyashiki
1 reference
Seiichi Okabe
1 reference
Tetsuzo Tauchi
1 reference
Yuko Tanaka
1 reference
Toshihiko Kitahara
1 reference
Shinya Kimura
1 reference
Taira Maekawa
1 reference
8 November 2013
1 reference
1 reference
1 reference
Identifiers
1 reference